CA2405190A1 - Simethicone solid oral dosage form - Google Patents

Simethicone solid oral dosage form Download PDF

Info

Publication number
CA2405190A1
CA2405190A1 CA002405190A CA2405190A CA2405190A1 CA 2405190 A1 CA2405190 A1 CA 2405190A1 CA 002405190 A CA002405190 A CA 002405190A CA 2405190 A CA2405190 A CA 2405190A CA 2405190 A1 CA2405190 A1 CA 2405190A1
Authority
CA
Canada
Prior art keywords
composition
dosage form
simethicone
oral dosage
solid oral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002405190A
Other languages
French (fr)
Other versions
CA2405190C (en
Inventor
Christopher E. Szymczak
James T. Walter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johnson and Johnson Consumer Inc
Original Assignee
McNeil PPC Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by McNeil PPC Inc filed Critical McNeil PPC Inc
Publication of CA2405190A1 publication Critical patent/CA2405190A1/en
Application granted granted Critical
Publication of CA2405190C publication Critical patent/CA2405190C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents

Abstract

The present invention provides a composition for forming a compressed solid dosage form that is a free-flowing compressible admixture of simethicone, an adsorbent, and an optional active agent, wherein the weight ratio of simethicone to adsorbent is at least 1:2.22. Also included are solid dosage forms made from a free-flowing compressible admixture of simethicone, an adsorbent, and an optional active agent, wherein the weight ratio of simethicone to adsorbent is at least 1:2.22.

Claims (28)

1. A composition for forming a compressed solid dosage form comprising a free-flowing compressible admixture of simethicone and an adsorbent, wherein the weight ratio of simethicone to adsorbent is at least about 1:2.22.
2. A composition of claim 1, wherein the weight ratio of simethicone to adsorbent is at least about 1:2.00
3. A composition of claim 1, wherein the adsorbent comprises a combination of silicified microcrystalline cellulose and magnesium aluminometasilicate.
4. A composition of claim 1, further comprising at least one additional active agent.
5. A composition of claim 4, wherein the active agent is selected from the group consisting of bisacodyl, famotadine, prucalopride, diphenoxylate, loperamide, lactase, mesalamine, bismuth, and pharmaceutically acceptable salts, esters, isomers, and mixtures thereof.
6. A composition of claim 5, wherein the active agent is loperamide, or pharmaceutically acceptable salts, esters, or isomers thereof.
7. A composition of claim 1 having at least 30 wt% simethicone.
8. A composition of claim 7, having from about 31 wt% to about 35 wt%
simethicone.
9. A composition of claim 1 having from about 19 wt% to about 27 wt%
silicified microcrystalline cellulose and having from about 31 wt% to about 39 wt% magnesium aluminometasilicate.
10. A composition of claim 9 having from about 23 wt% to about 27 wt%
silicified microcrystalline cellulose and from about 33wt% to about 37 wt%
magnesium aluminometasilicate.
11. A composition of claim 1, wherein the composition is compressed into a tablet having a hardness value of at least 2 kp/cm2.
12. A composition of claim 11, wherein the composition is compressed into a tablet having a hardness value of from about 5 to about 10 kp/cm~.
13. A solid oral dosage form comprising a compressed admixture of simethicone, silicified microcrystalline cellulose, and magnesium aluminometasilicate, wherein the simethicone is adsorbed on the silicified microcrystalline cellulose and magnesium aluminometasilicate.
14. A solid oral dosage form of claim 13, wherein the weight ratio of simethicone to adsorbent is at least 1:2.00.
15. A solid oral dosage form of claim 13, wherein the adsorbent comprises silicified microcrystalline cellulose and magnesium aluminometasilicate.
16. A solid oral dosage form of claim 13, further comprising at least one additional active agent.
17. A solid oral dosage form of claim 16, wherein the active agent is selected from the group consisting of bisacodyl, famotadine, prucalopride, diphenoxylate, loperamide, lactase, mesalamine, bismuth, and pharmaceutically acceptable salts, esters, isomers, and mixtures thereof..
18. A solid oral dosage form of claim 17, wherein the active agent is loperamide, or pharmaceutically acceptable salts, esters, or isomers thereof.
19. A solid oral dosage form of claim 13 having at least 30 wt% simethicone.
20. A solid oral dosage form of claim 19, having from about 31 wt% to about 35 wt% simethicone.
21. A solid oral dosage form of claim 13 having from about 19 wt% to about 27 wt% silicified microcrystalline cellulose and having from about 31 wt% to about 39 wt% magnesium aluminometasilicate.
22. A solid oral dosage form of claim 21 having from about 23 wt% to about 27 wt% silicified microcrystalline cellulose and from about 33wt% to about 37 wt% magnesium aluminometasilicate.
23. A solid oral dosage form of claim 13, wherein the composition is compressed into a tablet having a hardness value of at least 2 kp/cm2.
24 A solid oral dosage form of claim 13, wherein the composition is compressed into a tablet having a hardness value of from about 5 to about 10 kp/cm2.
25. A composition for forming a solid dosage form comprising a free-flowing compressible admixture of simethicone, silicified microcrystalline cellulose, magnesium aluminometasilicate.
26. A compressed solid dosage form comprising an admixture of simethicone, silicified microcrystalline cellulose, magnesium aluminometasilicate, wherein the weight ratio of simethicone to adsorbent is at least 1:2.00.
27. A composition of claim 5, wherein the active agent is bisacodyl, or pharmaceutically acceptable salts, esters, or isomers thereof.
28. A composition of claim 4, wherein the active agent is selected from the group consisting of acetaminophen, ibuprofen, naproxen, ketoprofen, cyclobenzaprine, meloxicam, rofecoxib, celecoxib, and pharmaceutically acceptable salts, esters, isomers, and mixtures thereof.
CA2405190A 2001-09-28 2002-09-25 Simethicone solid oral dosage form Expired - Fee Related CA2405190C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/966,441 2001-09-28
US09/966,441 US7101573B2 (en) 2001-09-28 2001-09-28 Simethicone solid oral dosage form

Publications (2)

Publication Number Publication Date
CA2405190A1 true CA2405190A1 (en) 2003-03-28
CA2405190C CA2405190C (en) 2010-11-09

Family

ID=25511414

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2405190A Expired - Fee Related CA2405190C (en) 2001-09-28 2002-09-25 Simethicone solid oral dosage form

Country Status (18)

Country Link
US (3) US7101573B2 (en)
EP (1) EP1297825B1 (en)
AR (1) AR036700A1 (en)
AT (1) ATE296619T1 (en)
AU (1) AU2002301259C1 (en)
BR (1) BR0204001A (en)
CA (1) CA2405190C (en)
CO (1) CO5390073A1 (en)
DE (1) DE60204403T2 (en)
DK (1) DK1297825T3 (en)
ES (1) ES2243664T3 (en)
HU (1) HUP0203176A2 (en)
MX (1) MXPA02009570A (en)
NZ (1) NZ521657A (en)
PL (1) PL204141B1 (en)
PT (1) PT1297825E (en)
RU (1) RU2362569C2 (en)
ZA (1) ZA200207755B (en)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6632429B1 (en) * 1999-12-17 2003-10-14 Joan M. Fallon Methods for treating pervasive development disorders
US7985420B2 (en) * 2000-04-28 2011-07-26 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
US6955821B2 (en) 2000-04-28 2005-10-18 Adams Laboratories, Inc. Sustained release formulations of guaifenesin and additional drug ingredients
US7838032B2 (en) * 2000-04-28 2010-11-23 Reckitt Benckiser Inc. Sustained release of guaifenesin
US8012504B2 (en) * 2000-04-28 2011-09-06 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
US20070053895A1 (en) * 2000-08-14 2007-03-08 Fallon Joan M Method of treating and diagnosing parkinsons disease and related dysautonomic disorders
US8030002B2 (en) 2000-11-16 2011-10-04 Curemark Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
US7101573B2 (en) * 2001-09-28 2006-09-05 Mcneil-Pcc, Inc. Simethicone solid oral dosage form
EP1509204A4 (en) * 2001-11-29 2005-07-13 Rettenmaier & Soehne Gmbh & Co Agglomerated particles including an active agent coprocessed with silicified microcrystalline cellulose
US7179488B2 (en) 2001-11-29 2007-02-20 Bob Sherwood Process for co-spray drying liquid herbal extracts with dry silicified MCC
SE0200895D0 (en) * 2002-03-22 2002-03-22 Astrazeneca Ab New pharmaceutical composition
US7341742B2 (en) * 2002-09-30 2008-03-11 L. Perrigo Company Simethicone containing tablet composition and method
EP1563837A1 (en) * 2004-02-03 2005-08-17 Ferrer Internacional, S.A. Hypocholesterolemic compositions comprising a statin and an antiflatulent agent
RU2384339C2 (en) * 2004-04-13 2010-03-20 Бёрингер Ингельхайм Интернациональ Гмбх Application of simethicon for patients predisposed to constipation
CA2565941A1 (en) * 2004-05-04 2005-11-10 Equitech Corporation Improved nsaid composition
US20060024384A1 (en) * 2004-07-29 2006-02-02 Giordano John A Compositions and methods for nutrition supplementation
US20060024409A1 (en) * 2004-07-29 2006-02-02 Everett Laboratories, Inc. Compositions and methods for nutrition supplementation
US20060198838A1 (en) * 2004-09-28 2006-09-07 Fallon Joan M Combination enzyme for cystic fibrosis
EP1862184A4 (en) * 2005-03-24 2012-12-19 Daiichi Sankyo Co Ltd Pharmaceutical composition
US20080058282A1 (en) 2005-08-30 2008-03-06 Fallon Joan M Use of lactulose in the treatment of autism
BRPI0615607A2 (en) * 2005-08-30 2011-05-24 Lek Pharmaceuticals pharmaceutical composition comprising perindopril or its salts
KR101252635B1 (en) * 2006-04-20 2013-04-10 (주)아모레퍼시픽 Pharmaceutical composition comprising a lipase inhibitor and a lipophilic oil absorbant and oral formulation prepared therefrom
US20080015260A1 (en) * 2006-07-13 2008-01-17 Kiel Laboratories, Inc. Pharmaceutical compositions having improved stability and methods for preparation and use
US20080038410A1 (en) * 2006-08-18 2008-02-14 Everett Laboratories, Inc. Compositions and methods for nutrition supplementation
WO2008057802A2 (en) 2006-10-27 2008-05-15 The Curators Of The University Of Missouri Compositions comprising at least one acid labile proton pump inhibiting agents, optionally other pharmaceutically active agents and methods of using same
WO2008056200A1 (en) * 2006-11-10 2008-05-15 Ranbaxy Laboratories Limited Oral pharmaceutical compositions of simethicone
JP2010510320A (en) 2006-11-21 2010-04-02 マクニール−ピーピーシー・インコーポレーテツド Modified release analgesic suspension
US9833510B2 (en) * 2007-06-12 2017-12-05 Johnson & Johnson Consumer Inc. Modified release solid or semi-solid dosage forms
US20090004248A1 (en) * 2007-06-29 2009-01-01 Frank Bunick Dual portion dosage lozenge form
CA2716367C (en) 2008-02-20 2015-05-26 The Curators Of The University Of Missouri Composition comprising a combination of omeprazole and lansoprazole, and a buffering agent, and methods of using same
US8658163B2 (en) 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
US8084025B2 (en) * 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
US9320780B2 (en) 2008-06-26 2016-04-26 Curemark Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
ES2732453T3 (en) 2008-07-01 2019-11-22 Curemark Llc Methods and compositions for the treatment of symptoms of neurological and mental health disorders
US10776453B2 (en) 2008-08-04 2020-09-15 Galenagen, Llc Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain
US20100092447A1 (en) 2008-10-03 2010-04-15 Fallon Joan M Methods and compositions for the treatment of symptoms of prion diseases
US9084784B2 (en) 2009-01-06 2015-07-21 Curelon Llc Compositions and methods for the treatment or the prevention of E. coli infections and for the eradication or reduction of E. coli surfaces
GB2480772B (en) 2009-01-06 2013-10-16 Curelon Llc Compositions and methods for the treatment or prevention of staphylococcus aureus infections and for the eradication or reduction of staphylococcus aureus
US20100247586A1 (en) * 2009-03-27 2010-09-30 Andreas Hugerth Multi-Portion Intra-Oral Dosage Form With Organoleptic Properties
JP5410819B2 (en) * 2009-04-09 2014-02-05 ライオン株式会社 Solid preparation containing wood creosote
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
US9511125B2 (en) 2009-10-21 2016-12-06 Curemark Llc Methods and compositions for the treatment of influenza
MX362974B (en) 2011-04-21 2019-02-28 Curemark Llc Compounds for the treatment of neuropsychiatric disorders.
WO2012170676A1 (en) 2011-06-08 2012-12-13 Sti Pharma, Llc Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration
CA2845929C (en) * 2011-09-08 2018-06-19 Novartis Ag Use of an aromatase inhibitor for the treatment of hypogonadism and related diseases
IN2014DN03373A (en) * 2011-10-27 2015-06-05 Borody Thomas J
ITMI20112221A1 (en) * 2011-12-05 2013-06-06 Altergon Sa STABLE FORMULATIONS IN JELLY CAPSULES SPRINGS OF PIASTRINICAL ANTI-AGGREGATES, OMEGA-3 FATTY ACIDS AND AMYLOSUS
WO2013095111A1 (en) 2011-12-14 2013-06-27 Disphar International B.V. Simethicone formulation
RU2491941C1 (en) * 2011-12-27 2013-09-10 Вадим Алексеевич Козловский Composite enterosorbent
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
MA41620A (en) 2015-05-14 2018-01-09 Abdi Ibrahim Ilac Sanayi Ve Ticaret A S PHARMACEUTICAL COMPOSITION CONSISTING OF SIMETHICONE AND OTILONIUM
JP6724537B2 (en) * 2015-05-26 2020-07-15 大正製薬株式会社 Solid formulation
US10166185B2 (en) * 2015-06-09 2019-01-01 J. Rettenmaier & Söhne Gmbh + Co Kg Excipient and oral solid dosage forms for oily drugs
WO2016201119A1 (en) * 2015-06-09 2016-12-15 J. Rettenmaier & Söhne Gmbh + Co Kg Excipient and oral solid dosage forms for oily drugs
EP3294269A1 (en) 2015-06-12 2018-03-21 Santa Farma Ilaç Sanayi A.S. Oral pharmaceutical composition comprising otilonium bromide and simethicone with certain bulk density and improved dissolution characteristics
EP3364955B1 (en) 2015-10-09 2022-04-20 RB Health (US) LLC Pharmaceutical formulation
MX2016016587A (en) * 2016-12-14 2018-06-13 Rhein Siegfried Sa De Cv Improved composition of lansoprazole and simeticone and method for preparing same.
EP4215187A1 (en) 2017-09-29 2023-07-26 Johnson & Johnson Consumer Inc. Solid simethicone particles and dosage form thereof
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses
FR3117780A1 (en) * 2020-12-22 2022-06-24 L'oreal ANHYDROUS COMPOSITION IN THE FORM OF A COMPACT POWDER COMPRISING A MAGNESIUM SALT AND MICROCRYSTALLINE CELLULOSE

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56169622A (en) * 1980-06-03 1981-12-26 Kissei Pharmaceut Co Ltd Method of making solid preparation from oily substance
US4744987A (en) * 1985-03-08 1988-05-17 Fmc Corporation Coprocessed microcrystalline cellulose and calcium carbonate composition and its preparation
US4851226A (en) 1987-11-16 1989-07-25 Mcneil Consumer Products Company Chewable medicament tablet containing means for taste masking
US4906478A (en) 1988-12-12 1990-03-06 Valentine Enterprises, Inc. Simethicone/calcium silicate composition
US5275822A (en) 1989-10-19 1994-01-04 Valentine Enterprises, Inc. Defoaming composition
US5073384A (en) 1989-10-19 1991-12-17 Valentine Enterprises, Inc. Maltodextrin/defoaming composition combinate
NZ235876A (en) 1989-11-01 1992-06-25 Mcneil Ppc Inc Pharmaceutical compositions containing effective amount of antidiarrheal composition and antiflatulent effective amount of simethicone
US5075114A (en) 1990-05-23 1991-12-24 Mcneil-Ppc, Inc. Taste masking and sustained release coatings for pharmaceuticals
CA2068402C (en) 1991-06-14 1998-09-22 Michael R. Hoy Taste mask coatings for preparation of chewable pharmaceutical tablets
JP3177707B2 (en) 1991-10-08 2001-06-18 堀井薬品工業株式会社 Gastrointestinal gas remover
SK279329B6 (en) * 1992-04-30 1998-10-07 Schering Corporation Stable hydrated cephalosporin dry powder, method of its preparation and formulation thereof
GR1002332B (en) * 1992-05-21 1996-05-16 Mcneil-Ppc Inc. Novel simethicone containing pharmaceutical compositions.
CA2110313C (en) * 1992-12-01 2004-10-26 Edward John Roche Pharmaceutical compositions containing a guanidinothiazole compound and antacids
FR2705966B1 (en) 1993-06-04 1995-08-25 Dow Corning Sa Antifoam compositions useful in particular for the treatment of gastric disorders.
JPH09504293A (en) * 1993-10-28 1997-04-28 ザ、プロクター、エンド、ギャンブル、カンパニー Fast dissolving dosage form containing magnesium aluminum silicate and multiple active ingredients
EP0659403B1 (en) 1993-12-15 2001-03-14 National Starch and Chemical Investment Holding Corporation Use of oil adsorbent natural polymer for cosmetic and pharmaceutical applications
IL139728A (en) * 1995-01-09 2003-06-24 Penwest Pharmaceuticals Compan Aqueous slurry composition containing microcrystalline cellulose for preparing a pharmaceutical excipient
US6106865A (en) * 1995-01-09 2000-08-22 Edward Mendell Co., Inc. Pharmaceutical excipient having improved compressibility
US5585115A (en) * 1995-01-09 1996-12-17 Edward H. Mendell Co., Inc. Pharmaceutical excipient having improved compressability
US6103260A (en) * 1997-07-17 2000-08-15 Mcneil-Ppc, Inc. Simethicone/anhydrous calcium phosphate compositions
US6190696B1 (en) * 1998-06-08 2001-02-20 Pieter J. Groenewoud Stabilized thyroxine medications
US6126967A (en) 1998-09-03 2000-10-03 Ascent Pediatrics Extended release acetaminophen particles
US7101573B2 (en) * 2001-09-28 2006-09-05 Mcneil-Pcc, Inc. Simethicone solid oral dosage form

Also Published As

Publication number Publication date
US7691409B2 (en) 2010-04-06
AU2002301259C1 (en) 2009-07-23
MXPA02009570A (en) 2004-07-30
US20070196468A1 (en) 2007-08-23
PL204141B1 (en) 2009-12-31
CA2405190C (en) 2010-11-09
US20100135982A1 (en) 2010-06-03
ES2243664T3 (en) 2005-12-01
PL356358A1 (en) 2003-04-07
HU0203176D0 (en) 2002-11-28
ZA200207755B (en) 2004-03-26
US20030091624A1 (en) 2003-05-15
AU2002301259B2 (en) 2009-01-22
RU2002125821A (en) 2004-03-27
DE60204403T2 (en) 2006-05-04
DE60204403D1 (en) 2005-07-07
EP1297825A1 (en) 2003-04-02
NZ521657A (en) 2004-05-28
BR0204001A (en) 2003-09-16
ATE296619T1 (en) 2005-06-15
HUP0203176A2 (en) 2004-07-28
PT1297825E (en) 2005-08-31
EP1297825B1 (en) 2005-06-01
AR036700A1 (en) 2004-09-29
RU2362569C2 (en) 2009-07-27
US7101573B2 (en) 2006-09-05
DK1297825T3 (en) 2005-09-26
CO5390073A1 (en) 2004-04-30

Similar Documents

Publication Publication Date Title
CA2405190A1 (en) Simethicone solid oral dosage form
AU728524B2 (en) Stable compositions containing N-propargyl-1-aminoindan
CA2199778A1 (en) Extended release formulation of venlafaxine
EP1287822A3 (en) Mesalazine controlled release oral pharmaceutical compositions
CA2320039A1 (en) Pharmaceutical composition comprising a combination of metformin and fibrate, and its use for the preparation of medicines intended to reduce hyperglycaemia
CA2280628A1 (en) Soft chewable tablets
CA2421685A1 (en) Soft tablet containing high molecular weight polyethylene oxide
CA2213700A1 (en) Pharmaceutical composition for piperidinoalkanol compounds
YU28104A (en) Oral dosage form for propiverine or its pharmaceutically acceptable salts with an extended release of the active ingredient
RS50377B (en) Inhibitors of renin-angiotensin system and application thereof
AU2003297260A1 (en) Fast-disintegrating solid dosage forms being not friable and comprising pullulan
NZ333822A (en) Tramadol multiple unit formulations comprising individual pellets of trmadol coated with one or more membrane layers for controlling release
CA2232450A1 (en) Oral pharmaceutical composition containing antimicrobial actives and sustained release pantoprazole
CA2394232A1 (en) Dual-release compositions of a cyclooxygenase-2-inhibitor
WO2007143163A3 (en) Pharmaceutical compositions for sustained release of phenyephrine
CA2391439A1 (en) Brittle-coating, soft core dosage form
WO2007134158A3 (en) Granules comprising calcium carbonate, a binder and a porosity increasing agent, processes of manufacturing, use in therapy
AU2616795A (en) Solid pharmaceutical compositions containing (s)-2-(4-isobutylphenyl)propionic acid active ingredient and microcrystalline cellulose and colloidal silica as excipients
WO2002056881A8 (en) Fenofibrate tablets
WO2007123883A3 (en) Oral dosage formulations and methods of preparing the same
WO2006117696A3 (en) Diastereoisomers of 4-hydroxyisoleucine and uses thereof
NO20023551L (en) Ibuprofen-containing active agent preparation
HUP0301072A2 (en) Tablet obtained by direct compression comprising 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid as active ingredient
EP1604658A3 (en) Pharmaceutical composition comprising ibuprofen and prochlorperazine
JP4805537B2 (en) Synergistic excipient composition

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20200925